PMID- 38390201
OWN - NLM
STAT- MEDLINE
DCOM- 20240226
LR  - 20240307
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 15
DP  - 2024
TI  - Clinical characteristics and degree of cardiovascular risk factor control in 
      patients with newly-diagnosed type 2 diabetes in Catalonia.
PG  - 1339879
LID - 10.3389/fendo.2024.1339879 [doi]
LID - 1339879
AB  - INTRODUCTION: Women with type 2 diabetes mellitus (T2DM) face a greater risk of 
      cardiovascular disease (CVD) and encounter challenges in managing cardiovascular 
      risk factors (CVRF); however, limited data are available in individuals with 
      newlydiagnosed T2DM. METHODS: This study aimed to examine differences between 
      women and men at the onset of T2DM in terms of clinical characteristics, 
      glycaemic status, and CVRF management. This was a retrospective cohort study 
      including subjects with newly-diagnosed T2DM from the System for the Development 
      of Research in Primary Care (SIDIAP) database in Catalonia (Spain). Sex 
      differences (Dif) were assessed at baseline and 1-year post-diagnosis, by 
      calculating the absolute difference of means or proportions. RESULTS: A total of 
      13,629 subjects with newly-diagnosed T2DM were analyzed. Women were older and had 
      a higher BMI than men. At baseline, women had higher total cholesterol [Dif 
      (95%CI) 10 mg/dL (9.1/10.8)] and low-density lipoprotein cholesterol (LDL-c) [Dif 
      (95%CI) 7 mg/dL (6.3/7.7)], while men had higher rates of smoking and alcohol 
      intake. Lipid target achievement was lower in women, in both primary prevention 
      (LDL-c < 100 mg/dL) [Dif (95%CI) -7.3 mg/dL (-10.5/-4.1)] and secondary 
      prevention (LDL-c < 70 mg/dL) [Dif (95%CI) -8.3 mg/dL (-17.3/0.7)], along with 
      lower statin and antiplatelet prescriptions, especially one year after diagnosis. 
      Changes in clinical and laboratory data one year post-diagnosis revealed that, in 
      the primary prevention group, men experienced greater improvements in total 
      cholesterol, LDL-c and triglycerides, while women had less success in achieving 
      CVRF control targets compared to men. Additionally, cardiovascular events, such 
      as coronary artery disease and peripheral artery disease increased more in men 
      than in women within the first year of diagnosis, especially in primary 
      prevention subjects. CONCLUSION: Differences between men and women CVRF are 
      already apparent at the onset of T2DM, particularly in primary prevention, with 
      notable differences in lipid profile and target level attainment.
CI  - Copyright (c) 2024 Ramirez-Morros, Franch-Nadal, Real, Miro-Catalina, Bundo, Vlacho 
      and Mauricio.
FAU - Ramirez-Morros, Anna
AU  - Ramirez-Morros A
AD  - Grup de Recerca Epidemiologica en Diabetes des de l'Atencio Primaria (DAP-CAT) 
      Group, Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari 
      per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), 
      Barcelona, Spain.
AD  - Gerencia Territorial de la Catalunya Central, Institut Catala de la Salut, Sant 
      Fruitos de Bages, Spain.
FAU - Franch-Nadal, Josep
AU  - Franch-Nadal J
AD  - Grup de Recerca Epidemiologica en Diabetes des de l'Atencio Primaria (DAP-CAT) 
      Group, Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari 
      per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), 
      Barcelona, Spain.
AD  - Center for Biomedical Research on Diabetes and Associated Metabolic Diseases 
      (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
FAU - Real, Jordi
AU  - Real J
AD  - Grup de Recerca Epidemiologica en Diabetes des de l'Atencio Primaria (DAP-CAT) 
      Group, Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari 
      per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), 
      Barcelona, Spain.
AD  - Center for Biomedical Research on Diabetes and Associated Metabolic Diseases 
      (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
AD  - Digital Health and Clinical Validation Center for Digital Health Solutions, 
      Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
FAU - Miro-Catalina, Queralt
AU  - Miro-Catalina Q
AD  - Gerencia Territorial de la Catalunya Central, Institut Catala de la Salut, Sant 
      Fruitos de Bages, Spain.
AD  - Health Promotion in Rural Areas Research Group, Unitat de Suport a la Recerca de 
      la Catalunya Central, Fundacio Institut Universitari per a la recerca a l'Atencio 
      Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), Sant Fruitos de Bages, Spain.
FAU - Bundo, Magdalena
AU  - Bundo M
AD  - Grup de Recerca Epidemiologica en Diabetes des de l'Atencio Primaria (DAP-CAT) 
      Group, Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari 
      per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), 
      Barcelona, Spain.
AD  - Primary Health Care Center Ronda Prim, Gerencia d'Ambit d'Atencio Primaria 
      Metropolitana Nord de Barcelona, Institut Catala de la Salut, Mataro, Spain.
FAU - Vlacho, Bogdan
AU  - Vlacho B
AD  - Grup de Recerca Epidemiologica en Diabetes des de l'Atencio Primaria (DAP-CAT) 
      Group, Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari 
      per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), 
      Barcelona, Spain.
AD  - Center for Biomedical Research on Diabetes and Associated Metabolic Diseases 
      (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
AD  - Institut de Recerca Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
FAU - Mauricio, Didac
AU  - Mauricio D
AD  - Grup de Recerca Epidemiologica en Diabetes des de l'Atencio Primaria (DAP-CAT) 
      Group, Unitat de Suport a la Recerca Barcelona, Fundacio Institut Universitari 
      per a la recerca a l'Atencio Primaria de Salut Jordi Gol i Gurina (IDIAPJGol), 
      Barcelona, Spain.
AD  - Center for Biomedical Research on Diabetes and Associated Metabolic Diseases 
      (CIBERDEM), Instituto de Salud Carlos III, Barcelona, Spain.
AD  - Institut de Recerca Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
AD  - Department of Endocrinology and Nutrition, Hospital Universitari de la Santa Creu 
      i Sant Pau, Barcelona, Spain.
AD  - Department of Medicine, University of Vic - Central University of Catalonia, Vic, 
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20240208
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Cholesterol, LDL)
SB  - IM
MH  - Humans
MH  - Female
MH  - Male
MH  - *Cardiovascular Diseases/diagnosis/epidemiology/etiology
MH  - Spain/epidemiology
MH  - Cholesterol, LDL
MH  - *Diabetes Mellitus, Type 2/diagnosis/epidemiology
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Heart Disease Risk Factors
PMC - PMC10883380
OTO - NOTNLM
OT  - cardiovascular risk factor
OT  - gender
OT  - newly diagnosis
OT  - sex
OT  - type 2 diabetes
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. The author(s) declared that they were an editorial board 
      member of Frontiers, at the time of submission. This had no impact on the peer 
      review process and the final decision.
EDAT- 2024/02/23 06:43
MHDA- 2024/02/26 06:43
PMCR- 2024/01/01
CRDT- 2024/02/23 03:52
PHST- 2023/11/16 00:00 [received]
PHST- 2024/01/17 00:00 [accepted]
PHST- 2024/02/26 06:43 [medline]
PHST- 2024/02/23 06:43 [pubmed]
PHST- 2024/02/23 03:52 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2024.1339879 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2024 Feb 8;15:1339879. doi: 
      10.3389/fendo.2024.1339879. eCollection 2024.